<DOC>
	<DOCNO>NCT01939366</DOCNO>
	<brief_summary>The purpose trial evaluate cebranopadol safe decrease pain patient compare placebo ( tablet contain active product ) compare marketed product contain pregabalin ( LyricaÂ® , indicate pain condition ) . Furthermore , trial undertaken find patient 's general health well-being improve trial treatment . The concentration cebranopadol blood investigate get well understanding absorbed gut , distribute broken body , eliminate body .</brief_summary>
	<brief_title>Cebranopadol Efficacy Safety Diabetic Patients Suffering From Chronic Pain Caused Damage Nerves</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Chronic Pain</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>write sign informed consent type 1 type 2 diabetes mellitus clinical diagnosis painful Diabetic Polyneuropathic Neuropathy ( DPN ) symptoms sign least 3 month must require medication ( e.g. , nonopioids opioids equivalent dose 160 mg oral morphine/day ) treatment pain due DPN least 1 month prior Visit 1 must dissatisfy current treatment ( term efficacy and/or tolerability ) . Medication treatment pain due DPN require least 4 7 consecutive day . blood glucose control diet , oral antihyperglycemic medication , and/or insulin least 3 month prior . Glycosylated hemoglobin ( HbA1C ) great 11 % baseline pain intensity score great equal 5 11point Numerical Rating Scale ( NRS ) without intake analgesic allocation . For last 3 day prior allocation treatment , 24 hour NRS score great equal 4 required woman childbearing potential must negative urine pregnancy test enrollment use medically acceptable highly effective method birth control ( willing use trial ) . presence pain could confound painful Diabetic Polyneuropathy ( DPN ) assessment , e.g . pain due nerve entrapment ( tarsal tunnel syndrome , osteoarthritis knee etc ) , peripheral vascular disease , radiculopathy , plantar fasciitis , tendonitis , mononeuritis multiplex , postherpetic neuralgia , complex regional pain syndrome , fibromyalgia . neuropathy due etiology diabetes , e.g . autoimmune disorder , inflammatory neuropathy ( e.g . chronic inflammatory demyelinate polyneuropathy ) , thyroid disease endocrine disorder ( diabetes ) , heavy metal toxic neuropathy , nutritional deficiency , metabolic disorder , vasculitis , infection , injury , paraneoplastic syndrome . severe extensive diabetic ulcer amputation due diabetes Charcot 's clinically significant disease laboratory finding , e.g. , significant unstable cardiac , vascular , pulmonary , gastrointestinal , endocrine , metabolic , neurological , psychiatric disorder . inability comply protocol intake trial medication , investigator 's opinion , might indicate participant unsuitable trial . condition require treatment medication allow take trial previous current alcohol drug abuse opioid dependency . severe functional hepatic impairment correspond ChildPugh classification C. history acute hepatitis impair renal function , creatinine clearance le 60 mL/min enrollment ( CockcroftGault calculate ) . history major gastrointestinal procedure ( e.g. , gastric bypass ) gastrointestinal condition ( e.g . acute diarrhea , blind loop syndrome , gastric dump syndrome , Whipple 's disease ) might affect absorption metabolism cebranopadol pregabalin . risk factor history torsade de pointes and/or mark prolongation QT interval ( e.g . heart failure , hypokalemia , bradycardia ) . history seizure disorder and/or epilepsy condition associate significant risk seizure disorder epilepsy discretion investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Painful Diabetic Peripheral Neuropathy</keyword>
</DOC>